加载中
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
最新数据
US$3.99
+US$0.41 · +11.45%
盘中时间采用ET。市场数据可能有所延迟。
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
盘中时间采用ET。市场数据可能有所延迟。
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2018年3月22日 | US$0.006Quarterly | — | 2018年3月29日 |
除息 2018年3月22日
US$0.006
Quarterly
支付日 2018年3月29日
报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG2766.49万1.35%15.57亿 USD0.75%US$51.30+4.08%
State Street SPDR S&P Biotech ETFXBI1312.8万0.13%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI1120.24万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM886.95万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF473.86万0.00%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO272.74万0.02%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB263.21万0.03%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA226.66万0.01%218.24亿 USD0.03%US$32.79+0.40%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
